[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [Neurocrine Biosciences, Inc.](/topic/neurocrine-biosciences-inc) ### Price: $XXXXXX  [Price 24-Hour Time-Series Raw Data](/topic/neurocrine-biosciences-inc/time-series/close.tsv) The stock price is likely to remain positive in the short term due to positive clinical trial data and strong sales, but minor downward pressure from missed EPS estimates may create some volatility. UBS raises Neurocrine Biosciences target to $195, driving positive sentiment. | 24-Hour | 7-Day | 30-Day | | ------- | ----- | ------ | | XXXX% | XXXX% | -XXXX% | **1-Year High**: $XXXXXX on 2025-01-30 **1-Year Low**: $XXXXX on 2025-04-08
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Price: $XXXXXX
Price 24-Hour Time-Series Raw Data
The stock price is likely to remain positive in the short term due to positive clinical trial data and strong sales, but minor downward pressure from missed EPS estimates may create some volatility. UBS raises Neurocrine Biosciences target to $195, driving positive sentiment.
| 24-Hour | 7-Day | 30-Day |
|---|---|---|
| XXXX% | XXXX% | -XXXX% |
1-Year High: $XXXXXX on 2025-01-30
1-Year Low: $XXXXX on 2025-04-08